Get the Stockscreener App
19.93
11.66%
-2.63
Pre-market:
20.40
0.47
+2.36%
Zenas Biopharma Inc stock is traded at $19.93, with a volume of 1.57M.
It is down -11.66% in the last 24 hours and down -38.85% over the past month.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
See More
Previous Close:
$22.56
Open:
$22.49
24h Volume:
1.57M
Relative Volume:
2.32
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+21.45%
1M Performance:
-38.85%
6M Performance:
+61.38%
1Y Performance:
+145.75%
1-Day Range:
$19.51
$22.49
1-Week Range:
$15.90
$22.60
52-Week Range:
$5.83
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Name
Zenas Biopharma Inc
Sector
Industry
Phone
857-271-2954
Address
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
19.93 | 1.21B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.92 | 79.26B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.24 | 49.47B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.26 | 48.47B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.29 | 38.37B | 4.98B | 69.59M | 525.67M | 0.5197 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-20-25 | Initiated | Wedbush | Outperform |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Citigroup | Buy |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
View All
Zenas Biopharma Inc Stock (ZBIO) Latest News
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1%Time to Sell? - MarketBeat
Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced - Trefis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - Chartmill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Assessing Zenas BioPharma (ZBIO) Valuation After Phase 3 INDIGO Success And CEO Share Purchase - Sahm
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up After Insider Buying Activity - MarketBeat
Sunday’s Insider Activity: Big Buys at Zenas, Hycroft, and Major NVDA Sell By Investing.com - Investing.com South Africa
Sunday’s Insider Activity: Big Buys at Zenas, Hycroft, and Major NVDA Sell - Investing.com
Ideas Watch: What are Zenas BioPharma Incs technical support levelsQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Insider Stock Purchases: January 10, 2026 - Quiver Quantitative
Zenas BioPharma Stock (ZBIO) Opinions on INDIGO Trial Results and CEO Investment - Quiver Quantitative
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys $819,000.00 in Stock - MarketBeat
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires 30,000 Shares of Stock - MarketBeat
Leon Moulder Jr Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock By Investing.com - Investing.com South Africa
Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock - Investing.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Does Zenas BioPharma (ZBIO) Pair INDIGO Success With Manageable China-Linked Risks In Its Strategy? - Sahm
Why Zenas BioPharma Inc. stock is favored by top institutionsJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - Улправда
What insider trading reveals about Zenas BioPharma Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - Улправда
Will Zenas BioPharma Inc. stock benefit from upcoming earnings reportsWeekly Investment Recap & Safe Investment Capital Preservation Plans - ulpravda.ru
Will Zenas BioPharma Inc. stock reach Wall Street targetsRisk Management & Reliable Momentum Entry Alerts - Улправда
Is Zenas BioPharma Inc. stock a bargain at current levels2025 Price Momentum & Weekly High Momentum Picks - Улправда
Zenas BioPharma Shares Phase III INDIGO Win as Obexelimab Cuts IgG4-RD Flare Risk 56% - MarketBeat
ZBIO tanks despite positive data from rare autoimmune diseases study - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Trading Up 11%Here's Why - MarketBeat
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Yahoo Finance UK
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study - sharewise.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas ... - Bluefield Daily Telegraph
Morgan Stanley Downgrades Zenas BioPharma (ZBIO) Rating and Pric - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% Following Analyst Downgrade - MarketBeat
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Canada
Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win - Yahoo Finance
Jefferies lowers Zenas Biopharma stock price target to $48 on trial data - Investing.com Canada
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions? - Yahoo Finance
Zenas BioPharma Stock Pre-Market (-4.0%) : Fallout From Phase 3 Data Disappointment - Trefis
Zenas BioPharma’s immune disorder drug meets main goal in late-stage trial - WHTC
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - ET Pharma
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio - Sahm
Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results - Investing.com Canada
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Investor's Business Daily
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Equal Weight" Rating by Morgan Stanley - MarketBeat
Zenas Biopharma Inc Stock (ZBIO) Financials Data
There is no financial data for Zenas Biopharma Inc (ZBIO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.67%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):